TRDA Entrada Therapeutics Inc
115
$15.70
$0.38
(2.48%)
| Watchers | 115 |
| 52-Wk Low | $10.62 |
| 52-Wk High | $18.44 |
| Market Cap | $517.19M |
| Volume | 71,074.00 |
| 52-Wk High | $18.44 |
| 52-Wk Low | $10.62 |
The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc.PR Newswire • about 2 months ago
The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc. The United Mitochondrial Disease...
Share to Feed
Related Stocks: TRDA...
H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on TRDA stock, giving a Buy rating on March 13. Ram Selvaraju has given h...
Entrada Therapeutics, Inc. (NASDAQ:TRDA Free Report) Investment analysts at William Blair lowered their Q1 2024 earnings per share estimates for Entrada Therapeutics in a research...
Extended Cash Runway and Progress in Duchenne Muscular Dystrophy Treatments Mark 2023 MilestonesRelated Stocks: TRDA...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Cash runway extended through the second quarter of 2026 $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 Completed dosing for third cohort of Phase 1...
Entrada Therapeutics CEO discloses sale of 1K shares...